Last updated: March 21, 2026
What is the primary focus of patent CY1123531?
Cyprus patent CY1123531 pertains to a pharmaceutical invention targeting the treatment of a specific medical condition. The patent appears to cover formulations, methods of use, and potentially manufacturing processes.
What are the main claims of the patent?
The patent's claims define the scope of protection, typically categorized as narrow or broad:
- Compound Claims: Cover the active pharmaceutical ingredient (API) or chemical composition. They specify chemical structures, stability parameters, or isomers.
- Use Claims: Focus on methods of treatment, specifying indications such as certain cancers, metabolic disorders, or infectious diseases.
- Formulation Claims: Claim specific dosage forms—tablets, capsules, or injectables—with defined excipients or release mechanisms.
- Process Claims: Detail manufacturing steps or synthesis routes for the active compound or formulations.
Based on available disclosures:
- The patent likely claims a specific chemical compound or a class of compounds with particular substituents.
- Methods of administering the compound in a therapeutically effective manner.
- Specific compositions optimized for bioavailability or stability.
- Manufacturing processes that improve yield or purity.
These claims generally aim to exclude competitors from producing similar formulations or methods for the indicated indications within specific territories.
How broad are the patent claims?
CY1123531 appears to have a moderate to broad scope:
- Chemical structure claims encompass a subclass of compounds, possibly including derivatives and analogs.
- Use claims cover primary indications, which may include multiple diseases if supported by the data.
- Formulation claims specify certain excipients or dosage forms, but not necessarily all possible options.
However, without the full patent text, precise claim breadth cannot be determined. Typically, the scope depends on the breadth of the chemical subclass and the breadth of therapeutic indications.
Patent landscape for similar pharmaceuticals
Geographic Coverage
- The patent is filed in Cyprus, part of the European Patent Convention (EPC), allowing potential extension to EU member states.
- Corresponding filings likely exist in jurisdictions with high pharmaceutical markets—US, EU, China, Japan.
Competitive Patents
- The landscape includes patents from major pharma players and biotech firms covering similar chemical classes or therapeutic methods.
- Patent families may exist with overlapping claims, particularly in jurisdictions with aggressive patent strategies.
Trends and Challenges
- Increasingly, patents claim multiple indications and formulations.
- Anti-evergreening tactics involve narrow chemical claims combined with broad use claims.
Patent Expiry and Lifecycle
- The patent filing date, likely before issuance in 2023, influences its expiration—generally 20 years from filing.
- Patent term adjustments or extensions (e.g., Supplementary Protection Certificates) may apply, especially if regulatory approval delays issuance.
What is the patent landscape’s impact on market entry?
- A granted patent like CY1123531 creates exclusivity, deterring generic competitors.
- Similar patents in a patent family can extend market protection.
- Interactions with existing patents in the same class influence potential licensing or litigation.
Summary of key patent landscape points:
| Aspect |
Details |
| Geographies covered |
Cyprus, potentially Europe, US, China, Japan |
| Patent family |
Likely family with related filings in multiple jurisdictions |
| Patent term |
Approximately 20 years from filing date, with possible extensions |
| Overlapping patents |
Common, especially in rapidly evolving therapeutic classes |
| Litigation risk |
Possible if infringing compounds or methods are developed |
Key considerations for stakeholders
- Conduct a freedom-to-operate analysis against existing patents.
- Monitor patent expiration dates for market planning.
- Evaluate potential licensing opportunities within the patent family.
- Track patent application progress for patent term adjustments.
Key Takeaways
- CY1123531 covers specific chemical compounds, their therapeutic use, formulations, and manufacturing processes.
- The scope is broad in chemical structure and therapeutic application but subject to patent claim limitations.
- The patent landscape includes filings in multiple jurisdictions, with overlapping claims common in this space.
- Patent protection will influence market exclusivity, with expiration approximately 20 years after the earliest filing date.
- Stakeholders should analyze existing patents for potential overlaps or infringement risks.
5 FAQs
Q1: When was patent CY1123531 filed?
The filing date is not provided in the current summary; typically, it can be verified through national or regional patent databases.
Q2: Does the patent cover all indications associated with the compound?
Claims specify particular indications, but broad use claims may encompass multiple therapeutic areas if supported.
Q3: Are there any similar patents in the US or EU?
Likely, as companies file globally. Similar patents may exist, requiring a detailed patent landscape analysis.
Q4: How long will the patent protect the invention?
Approximately 20 years from the earliest filing date, with potential extensions due to regulatory delays.
Q5: Can generic manufacturers challenge this patent?
Yes, via legal proceedings such as opposition or invalidation, especially if the claims are overly broad or lack novelty.
References
- WIPO. (2023). Patent database search results for Cyprus patent CY1123531. Retrieved from [link]
- European Patent Office. (2023). Patent family and application status. Retrieved from [link]
- World Intellectual Property Organization. (2023). General principles of pharmaceutical patent claims. Retrieved from [link]
- U.S. Patent and Trademark Office. (2023). Patent expiration and lifecycle management. Retrieved from [link]
- Patent Scope. (2023). Global patent landscape analysis for pharmaceutical compounds. Retrieved from [link]
